Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project

Drug Safety

Volumn 38, Issue 2, 2015, Pages 183-187

  Allen, Katherine C ^a,c   Champlain, Amanda H ^b,c   Cotliar, Jonathan A ^b,c   Belknap, Steven M ^b,c   West, Dennis P ^b,c   Mehta, Jayesh ^b,c   Trifilio, Steven M ^a,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LACTATE DEHYDROGENASE; RASBURICASE; URIC ACID; ANTIGOUT AGENT; URATE OXIDASE;

ACUTE LEUKEMIA; ADULT; AGE; ARTICLE; BODY WEIGHT; CHRONIC LEUKEMIA; CREATININE BLOOD LEVEL; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; FEMALE; GENDER; HUMAN; HYPERURICEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; ANAPHYLAXIS; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG SURVEILLANCE PROGRAM; PRACTICE GUIDELINE; RISK;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANAPHYLAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GOUT SUPPRESSANTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK; URATE OXIDASE;

EID: 84925537385     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0255-7     Document Type: Article

References (16)

1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.
2. Rasburicase [package insert]. Bridgewater: Sanofi-Aventis US LLC; 2009.
3. Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55(5 Suppl 3):S1–13.
4. Chester KA, Baker M, Mayer A. Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol. 2005;1(4):549–59.
5. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20(Suppl 6):63–9.
6. Bennett CL, Nebeker JR, Yarnold PR, et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007;167(10):1041–9.
7. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005;293(17):2131–40.
8. Trifilio SM, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant. 2011;46(6):800–5.
9. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006;37(11):997–1001.
10. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
11. Shimada M, Johnson RJ, May WS Jr, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant. 2009;24(10):2960–4.
12. Ejaz AA, Mu W, Kang DH, et al. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol. 2007;2(1):16–21.
13. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J. 2008;3(1):90–7.
14. Pui CH. Rasburicase: a potent uricolytic agent. Pharmacother. 2002;3(4):433–42.
15. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21(Suppl5):v9–12.
16. Rasburicase [package insert]. New York: Sanfoi-Synthelabo Inc; 2002.